American Renal Associates (ARA) Announces Quarterly Earnings Results

American Renal Associates (NYSE:ARA) announced its earnings results on Thursday. The company reported $0.19 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.13 by $0.06, Briefing.com reports. The firm had revenue of $211.02 million for the quarter, compared to the consensus estimate of $217.15 million. American Renal Associates had a positive return on equity of 19.60% and a negative net margin of 1.11%. The business’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.19 EPS.

ARA stock opened at $17.50 on Friday. American Renal Associates has a 1-year low of $9.91 and a 1-year high of $24.07. The company has a debt-to-equity ratio of 5.30, a current ratio of 1.07 and a quick ratio of 1.04. The stock has a market capitalization of $667.52 million, a PE ratio of 28.69, a price-to-earnings-growth ratio of 3.63 and a beta of 2.09.

Several research firms have recently weighed in on ARA. Zacks Investment Research lowered American Renal Associates from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 23rd. Bank of America lifted their price objective on American Renal Associates from $21.00 to $24.00 and gave the stock a “buy” rating in a research report on Tuesday, September 18th. Leerink Swann raised American Renal Associates from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $22.00 to $26.00 in a research report on Thursday, August 23rd. SunTrust Banks reissued a “buy” rating and issued a $25.00 price objective on shares of American Renal Associates in a research report on Thursday, August 9th. Finally, ValuEngine raised American Renal Associates from a “hold” rating to a “buy” rating in a research report on Friday, August 3rd. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. American Renal Associates has a consensus rating of “Buy” and a consensus target price of $22.60.

Several hedge funds have recently bought and sold shares of ARA. Dimensional Fund Advisors LP increased its position in American Renal Associates by 94.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 495,708 shares of the company’s stock valued at $7,818,000 after buying an additional 240,542 shares in the last quarter. BlackRock Inc. increased its position in American Renal Associates by 33.2% in the 2nd quarter. BlackRock Inc. now owns 816,103 shares of the company’s stock valued at $12,869,000 after buying an additional 203,211 shares in the last quarter. Renaissance Technologies LLC increased its position in American Renal Associates by 111.2% in the 2nd quarter. Renaissance Technologies LLC now owns 347,500 shares of the company’s stock valued at $5,480,000 after buying an additional 183,000 shares in the last quarter. OppenheimerFunds Inc. increased its position in American Renal Associates by 44.3% in the 2nd quarter. OppenheimerFunds Inc. now owns 403,351 shares of the company’s stock valued at $6,361,000 after buying an additional 123,773 shares in the last quarter. Finally, Citadel Advisors LLC increased its position in American Renal Associates by 937.3% in the 2nd quarter. Citadel Advisors LLC now owns 128,282 shares of the company’s stock valued at $2,023,000 after buying an additional 115,915 shares in the last quarter. 92.67% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.thelincolnianonline.com/2018/11/10/american-renal-associates-ara-announces-quarterly-earnings-results.html.

American Renal Associates Company Profile

American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.

See Also: Why is the ex-dividend date different from the record date?

Earnings History for American Renal Associates (NYSE:ARA)

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply